Clinical trials: Recurrent Primary Peritoneal Cavity Cancer
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
This phase II trial is studying how well cediranib maleate works in treating patients with persistent, recurrent, or refractory advanced ovarian epithelial, peritoneal cavity, or fallopian tube cancer.
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Trial name
- NCT00278343
- Testing
- cediranib maleate, laboratory biomarker analysis
- Where
- 28 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer
This phase II trial is studying how well giving sorafenib together with gemcitabine works in treating patients with recurrent or refractory ovarian cancer or primary peritoneal cancer.
- Trial name
- NCT00096395
- Testing
- gemcitabine hydrochloride, sorafenib tosylate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Peritoneal Cavity Cancer
Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00825201
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, liquid chromatography, mass spectrometry
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This phase II trial is studying how well giving bevacizumab together with erlotinib works in treating patients with recurrent or metastatic ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Trial name
- NCT00126542
- Testing
- bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This is a Phase I, multicenter, open-label, dose-escalation study of single-agent D4064A administered by IV infusion to patients with recurrent or persistent epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), and…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT00753480
- Testing
- D4064A
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Genentech, Inc.
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Randomized phase III trial to compare the effectiveness of tamoxifen with that of thalidomide in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer
- Trial name
- NCT00041080
- Testing
- tamoxifen citrate, thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Estrogen Receptor Negative, HER2/Neu Negative
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
This phase I trial studies the side effects and the best dose of veliparib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with ovarian cancer, fallopian tube cancer, or primary…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT01145430
- Testing
- Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study
- Where
- 6 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody, paclitaxel, and interferon alfa in treating patients who have ovarian cancer.
- Trial name
- NCT00002734
- Testing
- recombinant interferon alfa, chemotherapy, paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back…
- Conditions
- Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
- Trial name
- NCT02839707
- Testing
- Atezolizumab, Bevacizumab, Computed Tomography
- Where
- 919 sites in United States, Puerto Rico
- Volunteers
- 444 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
This randomized phase II trial studies how well paclitaxel when given together with or without pazopanib hydrochloride works in treating patients with ovarian epithelial, fallopian tube, or peritoneal cavity cancer that is…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01468909
- Testing
- Laboratory Biomarker Analysis, Paclitaxel, Pazopanib Hydrochloride
- Where
- 142 sites in United States
- Volunteers
- 106 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This phase II trial studies how well tivozanib works in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer
- Trial name
- TIVO (NCT01853644)
- Testing
- Tivozanib
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Fallopian Tube Cancer, Ovarian Cancer
Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma
The purpose of this study is to evaluate the effectiveness of the combination of Avastin and Docetaxel in the treatment of women with platinum sensitive recurrent epithelial ovarian cancer within 12 months of platinum…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Malignant Tumor of Peritoneum
- Trial name
- NCT00504257
- Testing
- Avastin, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Fallopian Tube Cancer, Ovarian Cancer
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Topotecan may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00045175
- Testing
- 7-hydroxystaurosporine, topotecan hydrochloride
- Where
- 3 sites in Canada
- Volunteers
- 33 people
- Sponsor
- University Health Network, Toronto
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Fallopian Tube Cancer, Ovarian Cancer
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining two or more drugs may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00014690
- Testing
- plevitrexed, topotecan hydrochloride
- Where
- United States
- Sponsor
- AstraZeneca
Ovarian Cancer
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The purpose of this study is to estimate the maximum tolerated doses (MTD) of CRLX101 when administered in combination with weekly paclitaxel in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary…
- Trial name
- NCT02389985
- Testing
- CRLX101, Paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- NewLink Genetics Corporation
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I clinical trial studies the side effects of sirolimus and NY-ESO-1 protein with MIS416 in treating patients stage II-IV ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIA Fallopian Tube Cancer
- Trial name
- NCT02833506
- Testing
- Laboratory Biomarker Analysis, Recombinant NY-ESO-1 Protein, Sirolimus
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
This phase II trial studies the side effects of ONC201 and paclitaxel and how well they work in treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back…
- Conditions
- Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
- Trial name
- NCT04055649
- Testing
- Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Ira Winer
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
This phase II trial compares copanlisib and olaparib to standard of care chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that did not respond to previous platinum-based chemotherapy…
- Conditions
- Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma
- Trial name
- NCT05295589
- Testing
- Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging
- Where
- 5 sites in United States
- Sponsor
- National Cancer Institute (NCI)